RESEARCH ARTICLE

Designing a multi-layered surveillance approach to detecting SARS-CoV-2: A modelling study [version 1; peer review: 2 approved with reservations]

Yang Liu ¹, Wenfeng Gong^{2*}, Samuel Clifford ^{1*}, Maria E. Sundaram³, CMMID COVID-19 Working Group, Mark Jit^{1,4}, Stefan Flasche ^{1*}, Petra Klepac^{1,5*}

¹Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, NW63JP, UK

²Bill and Melinda Gates Foundation, Seattle, Washington, USA

³Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

⁴School of Public Health, University of Hong Kong, Hong Kong, Hong Kong

⁵Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, UK

* Equal contributors

V1 First published: 16 Sep 2020, 5:218
<https://doi.org/10.12688/wellcomeopenres.16256.1>
 Latest published: 16 Sep 2020, 5:218
<https://doi.org/10.12688/wellcomeopenres.16256.1>

Abstract

Background: Countries achieving control of COVID-19 after an initial outbreak will continue to face the risk of SARS-CoV-2 resurgence. This study explores surveillance strategies for COVID-19 containment based on polymerase chain reaction tests.

Methods: Using a dynamic SEIR-type model to simulate the initial dynamics of a COVID-19 introduction, we investigate COVID-19 surveillance strategies among healthcare workers, hospital patients, and community members. We estimate surveillance sensitivity as the probability of COVID-19 detection using a hypergeometric sampling process. We identify test allocation strategies that maximise the probability of COVID-19 detection across different testing capacities. We use Beijing, China as a case study.

Results: Surveillance subgroups are more sensitive in detecting COVID-19 transmission when they are defined by more COVID-19-specific symptoms. In this study, fever clinics have the highest surveillance sensitivity, followed by respiratory departments. With a daily testing rate of 0.07/1000 residents, via exclusively testing at fever clinic and respiratory departments, there would have been 598 [95% eCI: 35, 2154] and 1373 [95% eCI: 47, 5230] cases in the population by the time of first case detection, respectively. Outbreak detection can occur earlier by including non-syndromic subgroups, such as younger adults in the community, as more testing capacity becomes available.

Conclusions: A multi-layer approach that considers both the surveillance sensitivity and administrative constraints can help identify the optimal allocation of testing resources and thus inform COVID-19

Open Peer Review

Approval Status ? ?

	1	2
version 1		
16 Sep 2020	view	view
1. Sen Pei , Columbia University, New York, USA		
2. Weibing Wang , Fudan University, Shanghai, China		

Any reports and responses or comments on the article can be found at the end of the article.

surveillance strategies.

Keywords

surveillance, testing, COVID-19, SARS-CoV-2, hospital, non-pharmaceutical intervention, community health, community screening

This article is included in the [Coronavirus \(COVID-19\)](#) collection.

Corresponding author: Yang Liu (Yang.Liu@lshtm.ac.uk)

Author roles: **Liu Y:** Conceptualization, Data Curation, Formal Analysis, Software, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Gong W:** Conceptualization, Data Curation, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Clifford S:** Formal Analysis, Software, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Sundaram ME:** Writing – Original Draft Preparation, Writing – Review & Editing; **Jit M:** Conceptualization, Formal Analysis, Writing – Original Draft Preparation, Writing – Review & Editing; **Flasche S:** Conceptualization, Formal Analysis, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Klepac P:** Conceptualization, Formal Analysis, Software, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: YL and MJ are funded by the National Institute for Health Research (UK)(16/137/109), the Bill & Melinda Gates Foundation (INV-003174), and the European Commission (101003688). PK is funded by the Royal Society (UK)(RP\EA\180004), the Bill & Melinda Gates Foundation (INV-003174), and the European Commission (101003688). SF and SC are funded through a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant Number 208812). MES is funded by the National Institute of Allergy and Infectious Diseases (US)(T32AI074492). YL and SC are funded by UK Medical Research Council grant MC_PC_19065, “Understanding the dynamics and drivers of the COVID-2019 epidemic using real-time outbreak analytics”. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care. This research is partly funded by the Bill & Melinda Gates Foundation (INV-003174). The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Bill & Melinda Gates Foundation.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Liu Y *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Liu Y, Gong W, Clifford S *et al.* **Designing a multi-layered surveillance approach to detecting SARS-CoV-2: A modelling study [version 1; peer review: 2 approved with reservations]** Wellcome Open Research 2020, 5:218 <https://doi.org/10.12688/wellcomeopenres.16256.1>

First published: 16 Sep 2020, 5:218 <https://doi.org/10.12688/wellcomeopenres.16256.1>

Introduction

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was first detected in Wuhan, China towards the end of 2019¹. On 11 March 2020, the World Health Organization declared COVID-19 a global pandemic². Within eight months of its emergence, COVID-19 has led to over 25 million reported cases and over 850,000 reported deaths globally (as of 7th September 2020)³. Many countries and regions have succeeded in reducing COVID-19 incidence after the initial epidemics, such as China and New Zealand.

Nevertheless, it is unlikely that SARS-CoV-2 will be eradicated in the near future. Given the high transmissibility of the pathogen^{4,5}, the non-trivial proportion of infectious individuals showing mild to no symptoms⁶, the non-specific nature of symptoms⁷, the highly intertwined global travel network⁸, and a lack of effective pharmaceutical measures for prevention or therapy⁹, countries that successfully contain the initial spread of COVID-19 will likely continue to face risks introduced by international travellers and unidentified local cases. With physical distancing measures gradually easing, sporadic infection clusters have already been observed¹⁰.

To prevent these sporadic infection clusters from seeding new epidemics, rapid infection detection is vital. Containment strategies, such as case isolation and contact tracing, rely on early detection of COVID-19 infections and can quickly be overwhelmed if transmission remains undetected for too long. Thus, sustainable, cost-effective, and highly sensitive surveillance systems capable of early warning for potential SARS-CoV-2 resurgence can guide ongoing implementation of control measures and are essential to the success of COVID-19 containment¹¹.

This study explores different surveillance strategies that maximise the probability of COVID-19 detection using polymerase chain reaction (PCR) while minimising the material and human resources required. We use Beijing as a case study and explore the potential benefits of conducting COVID-19 surveillance among healthcare workers, hospital patients, and regular community members. Hospital settings further break down to

different layers, from fever clinic, respiratory departments, to general hospital departments. Fever clinics, a triage system that emerged during the 2003 outbreak of SARS-CoV, play a crucial role in COVID-19 response in China¹² and could be considered a potentially effective surveillance option elsewhere. The framework introduced is relevant to containment strategies in countries exiting the initial phases of COVID-19 epidemics, where only a small number of cases are observed sporadically.

Methods

The epidemic process

We simulate the spread of SARS-CoV-2 using a deterministic age-stratified compartmental SEIR-type model (Figure 1)¹³. Additionally, the infectious compartment is split into I^{pc} , I^c and I^{sc} to account for differences in disease progression. The compartment I^c represents infectious individuals whose symptoms are sufficiently severe (“clinical” illnesses) for them to seek healthcare; the compartment I^{pc} represents the pre-clinical infectious individuals who have not yet develop symptoms for them to seek care for COVID-19; the compartment I^{sc} represents infectious individuals who may not seek healthcare for COVID-19 due to mild symptoms (“subclinical” illnesses). Individuals in the compartment I^{pc} and I^{sc} may seek care for other causes. All of I^{pc} , I^c and I^{sc} contribute to the force of infection (FOI) although subclinical individuals may transmit diseases at a lower rate^{14,15}. This framework has been used to study COVID-19 in several previous studies^{6,15,16}. More details about this model can be found in the *Extended data* Section 1¹⁷.

Chau *et al.* discovered that COVID-19 patients may remain PCR positive for up to 10 days after hospital admission, at which point they may no longer be infectious¹⁸. To accounts for this, building upon the existing model structure, we break the R compartment (“Removed”, a state in which individuals are no longer able to transmit illness) down into R_+^{sc} (PCR-positive individuals from I^{sc}), R_+^c (PCR-positive individuals from I^c) and R_- (PCR-negative individuals). Based on the results of Chau *et al.*¹⁸, we assume that PCR is more likely to detect a COVID-19 infection in clinical infectious compartments (I^{pc} and I^c) compared to the subclinical infectious compartment (I^{sc}); in infectious compartments (I^{pc} , I^c , and I^{sc}) compared to

Figure 1. Conceptual diagram of the COVID-19 dynamic model. Solid box indicates compartments that affect the force of infection; dashed box indicates compartments detectable by PCR-based surveillance. S : susceptible; E : exposed; I^{pc} : pre-clinical infectious; I^c : Clinical infectious; I^{sc} : sub-clinical infectious; R_+^c : PCR-positive removed following I^c ; and R_+^{sc} : PCR-positive removed following I^{sc} ; R_- : PCR-negative removed.

post-infectious compartments (R_+^c and R_+^{sc}). The PCR diagnostic sensitivity in the context of COVID-19 is digitized from Chau *et al.*¹⁸. PCR diagnostic specificity, on the other hand, is assumed to be 100%, consistent with Grassly *et al.*¹⁹. Potential false-positive results may be compensated by double-testing positive samples.

Importantly, we assume that at the start of the second wave there is a sufficiently high number of susceptible individuals that early epidemic dynamics are not limited by widespread and long-lasting population immunity (for which there is limited evidence)²⁰.

The age structure of the model considers five-year age categories for 0–74 year-olds and a single group for everyone above 75 years of age. We obtained other model parameters from the literature or online database (Table 1). At the start of the simulation, we assume there was one exposed (infected but not yet infectious) younger adult (i.e., 15–64 year-old); the population is otherwise susceptible, consistent with low seropositivity found in serological surveys^{21,22}. A meta-analysis by Davies *et al.* showed an unmitigated reproduction number of COVID-19 to be 2.7 (95% critical interval: 1.6–3.9)¹⁵. Here, we assume an effective reproduction number (R_e) of 2 that reflects a 25% reduction from 2.7 as a result of public health measures

Table 1. Parameters table. Respiratory illnesses are defined as “respiratory infections and tuberculosis” (excluding latent tuberculosis infections), “chronic respiratory diseases”, and “Tracheal, bronchus, and lung cancer”.

Parameters	Baseline Scenario	Sensitivity Analyses	Source
Epidemiological parameters			
Latent period	2.6 days	1 – 4 days	Li <i>et al.</i> ¹ Backer <i>et al.</i> ²³ Davies <i>et al.</i> ¹⁵
Pre-clinical infectious period	2.4 days	1 – 3 days	Liu <i>et al.</i> ²⁴ He <i>et al.</i> ²⁵
Clinical infectious period	3.6 days	3 – 6 days	He <i>et al.</i> ²⁵
Subclinical infectious period (assumed to be the same as the sum of pre-clinical and clinical infectious periods)	6 days	5 and 8 days	Davies <i>et al.</i> ¹⁵
Age-specific clinical fraction (relative that develop symptoms after infection)	0.28 – 0.69	-	Davies <i>et al.</i> ⁶
Relative susceptibility	0.44 - 1 (Baseline group: 60–69 year-olds)	-	Davies <i>et al.</i> ⁶
Relative transmissibility of subclinical infections (compared to clinical)	0.14	0.5	Keeling <i>et al.</i> ¹⁴ Davies <i>et al.</i> ¹⁵
Mitigated reproduction number	2	1.4, 2.7	Assumed based on Davies <i>et al.</i> ¹⁵
Number of contacts between individuals of different ages	3 – 20 contacts/ day	-	Prem <i>et al.</i> ¹⁶
Population (counts and age distribution)	549,734 - 2,686,112 / age group	-	China Statistics Yearbook ²⁶
Surveillance parameters			
Prevalence of influenza-like illness (ILI)	3%	2%, 6%	Chinese National Influenza Weekly Reports ²⁷
Annual prevalence of all respiratory illnesses [^]	~10%	-	GBD 2017 Disease and Injury Incidence and Prevalence Collaborators ²⁸
Maximum routine testing capacity per population-day	4.15/1000		Wan ²⁹
Daily Fever Clinic Service Capacity, per population-day	0.07/1000		Gong ³⁰

Parameters	Baseline Scenario	Sensitivity Analyses	Source
Daily Respiratory Department Service Capacity, per population-day	1.35/1000	0.81-1.89/1000	Zhang <i>et al.</i> ³¹
Healthcare worker to patient ratio	1:3		Chinese National Influenza Weekly Report ²⁷ Zhang <i>et al.</i> ³¹ China Health Statistics Yearbook ³²
PCR diagnostic sensitivity for SARS-CoV-2	Clinical: 30%~90% Subclinical: 18%~46%		Chau <i>et al.</i> ¹⁸
PCR diagnostic specificity for SARS-CoV-2	100%		Grassly <i>et al.</i> ¹⁹

A

(e.g., physical distancing in public). Additionally, R_e of 2.7 (unmitigated) and 1.4 (50% reduction) are explored as possible scenarios. At each R_e level, sensitivity analyses given different sets of epidemiological parameters are provided, with results presented as Uncertainty Range (UR).

Surveillance layers and subgroups

Surveillance layers are settings where COVID-19 surveillance is possible; surveillance subgroups are defined by specific characteristics (e.g., age and occupation) within a given surveillance layer. In this study, we consider three surveillance layers and nine surveillance subgroups within these surveillance layers (Table 2).

Fever clinics are triage systems established in China during the 2003 SARS epidemic to limit the spread of pandemic pathogens in hospital settings and allow rapid detection³³. Telephone-based triaging systems combined with drive-through testing centres used in the United States (e.g., Georgia³⁴) during the COVID-19 pandemic are motivated similarly. A fever clinic is part of a hospital and often staffed by healthcare workers (HCWs) from respiratory departments or clinical laboratories. In the context of COVID-19, anyone with any respiratory symptoms and potential exposure to a confirmed case, as well as anyone with a combination of fever and any respiratory symptoms but no known exposure, are encouraged to present to fever clinics in China³⁵. In China, the national sentinel influenza surveillance system reports the proportion of all outpatients with influenza-like illness (ILI) (defined as fever $\geq 38^\circ\text{C}$ and cough or sore throat)²⁷. In this study, the percentage of ILI among all outpatients is used to model the background rate of fever clinic visits for non-COVID-19 related causes.

For public health surveillance, this study assumes 1) that individuals with clinical respiratory illness who seek care would be captured by a surveillance system in either fever clinics or respiratory departments; 2) that those with a subclinical COVID-19 infection who are seeking care for non-respiratory causes may be detected in other hospital departments; 3) that those with a COVID-19 infection who do not actively seek care may be detected in the community whether they exhibit symptoms or

not. Specific pathways to the detection of different surveillance layers and subgroups are shown in Table 2.

The risk of a susceptible individual, whether an HCW or not, contracting COVID-19 while present in a fever clinic or respiratory department is elevated due to the concentration of infected individuals. HCWs may face a higher COVID-19 infection risk than patients do in these locations due to prolonged exposures. In this study, the expected number of infectious encounters for HCW and non-HCW adults are calculated by taking the product of the number of contacts (either patient or non-patient, digitised from 36) and the corresponding COVID-19 prevalence (inpatient or non-patient settings). The HCW to non-HCW ratios of infectious encounters (α) is then used as a risk multiplier for different HCW subgroups. More details can be found in the Extended Data Section 2¹⁷.

Surveillance sensitivity and probability of detection

The surveillance sensitivity ($\phi_{i,k,t}$) is the probability of detecting at least one individual infectious with COVID-19 in a subgroup i on a given day t (since the first case) is characterised by a hypergeometric distribution:

$$P_{i,t}(q \geq 1; N_i, \psi_i N_i p_{i,t}, k) = \phi_{i,k,t} \quad (\text{eq.1})$$

where N_i is the number of all members in subgroup i , $p_{i,t}$ is the proportion infected in subgroup i on day t , ψ_i is the PCR diagnostic sensitivity in subgroup i , $\psi_i N_i p_{i,t}$ is the total number of detectable infected individuals in subgroup i , k is the number of individuals tested on day t , and q is the number of infectious individuals identified through testing (of k individuals). Different from the binomial distribution, hypergeometric distribution describes the probability of detection without replacement, and thus more appropriate in capturing healthcare-seeking behaviour. In this study, $p_{i,t}$ depends on the surveillance pathways outlined in Table 2. For example, for a patient seeking care at a fever clinic, the probability that they are infectious with SARS-CoV-2 is:

$$p_{fc.pat,t} = \frac{I_t^c}{I_t^c + ILI_t} \quad (\text{eq.2})$$

Table 2. Surveillance pathways.

Surveillance Layers	Surveillance Subgroups	Descriptions	HCW					Non-HCW				
			I^{pc}	I^c	R_+^c	I^{sc}	R_+^{sc}	I^{pc}	I^c	R_+^c	I^{sc}	R_+^{sc}
Healthcare Worker Surveillance	Fever Clinic	HCW working in different hospital departments	x			x	x	-	-	-	-	-
	Respiratory Department		x			x	x	-	-	-	-	-
	Other Hospital Departments		x			x	x	-	-	-	-	-
Patient-based Surveillance	Fever Clinic	Patients seeking care with influenza-like symptoms		x				x				
	Respiratory Department	Patients seeking care for any respiratory conditions		x				x				
	Other Hospital Departments	Patients seeking care for any non-respiratory conditions	x		x	x	x	x		x	x	x
Community-based Surveillance	Children	≤ 15 years	x	x	x	x	x	x	x	x	x	x
	Younger Adults	16 – 64 years	x	x	x	x	x	x	x	x	x	x
	Older Adults	≥ 65 years	x	x	x	x	x	x	x	x	x	x

where ILI_t is the number of non-COVID-19 patients who could be triaged into fever clinics based on influenza-like illness (ILI). This equation does not include I^{pc} and I^{sc} as they would not be triaged into a fever clinic by definition. Parameters used to capture the proportions of the patient population who would be seen at fever clinics, respiratory departments, and other hospital departments are summarised in Table 1.

The probability of an individual in subgroup i on day t testing positive ($p_{i,t}$) decreases as the background population size increases (under the assumption of perfect specificity). In the example above, the background population in a fever clinic is captured by ILI_t . In respiratory departments, the background population is the number of patients who visit respiratory departments for all non-COVID-19 respiratory causes (Rsp_t). Thus, at any given time t , Rsp_t must be at least as large as ILI_t . The proportion of COVID-19-infected patients in fever clinics $p_{fc,pat,t}$ is always larger than that in respiratory departments ($p_{rsp,pat,t}$) by definition.

We assume that HCWs who have clinical respiratory illness behave identically to other non-HCW individuals with clinical respiratory illness, and hence will attend fever clinics or respiratory departments. Surveillance targeting the HCW subgroups will only capture those current in the I^{pc} , I^c , or R_+^{sc} (see Table 2). These HCWs will face a higher risk of infection due to occupational exposure ($\alpha_{fc,hcw,t}$). For example, the probability of an HCW working at a fever clinic to be PCR detectable on a given day t can be expressed as:

$$p_{fc,hcw,t} = \frac{I_t^{pc} + I_t^{sc} + R_+^{sc}}{pop} \alpha_{fc,hcw,t} \quad (\text{eq.3})$$

where $\alpha_{fc,hcw,t}$ is the increased risk multiplier for an HCW working at a fever clinic on day t . The probability π_t of detecting COVID-19 infection by time t in at least one subgroup using k tests per day can be expressed as:

$$\pi_{k,t} = 1 - \prod_i \prod_t (1 - \phi_{i,k,t}) \quad (\text{eq.4})$$

Comparing fever clinics and respiratory departments

The testing capacity needed at the respiratory departments to achieve a similar probability of COVID-19 detection while testing at maximum capacity at fever clinics (1,600 tests/day or 0.07 tests per thousand residents per day (t/k/day)) is found using mean absolute errors. Then, at different levels of daily testing capacity, we estimate the time it takes for the outbreak to surveillance processes simulated, a corresponding time at which we become aware of the on-going transmission is generated. We extract the corresponding cumulative incidences at these times of transmission detection from the results of the dynamic model, forming a probability distribution of epidemic sizes by the time first COVID-19 cases are detected. The relevant uncertainty is expressed using the middle 95% of the simulated sample, i.e., the 95% empirical confidence intervals (eCI).

Characteristics of surveillance systems

In practice, surveillance systems are constrained by human and capital resources. The number of samples that can be tested is constrained by factors like local laboratory capacity. By 22 April 2020, Wuhan had tested as many as 63,000 samples in a single day, approximately 6 t/k/day³⁷. However, testing at such a high level may not be sustainable. Daily testing capacities in South Korea and the United Kingdom are about 1 to 3 tests per 1,000 residents^{38,39}. We cap the maximum daily testing

capacity at 4.15 tests per 1,000 residents, consistent with the observed testing capacity in Beijing²⁹. In a city with population size and age structure of Beijing (with a population of 22 million as of 2017)⁴⁰, this translates to a maximum daily testing capacity of approximately 100,000 tests per day. Additionally, we assume a maximum of 10% HCWs at non-fever clinic hospital departments, and 30% of HCWs at fever clinics can be tested each day as a part of HCW surveillance to minimise interference with every-day work. We consider optimal resource allocation strategies by gradually incrementing the testing capacity in increments of 200.

The number of tests performed in the individual subgroups is also constrained by the number of individuals available for testing, driven by the local healthcare infrastructures and demographics. In this study, we extracted values for Beijing (Table 1). These values may apply to other large cities in the region.

Determining the most efficient strategy

We consider a wide range of testing capacities between 0 and 100,000 tests daily, with increments of 200 tests, totalling 501 different levels of testing capacity. Therefore, the number of daily tests available at level n is $200(n-1)$. We then determined how these $200(n-1)$ tests should be allocated across different subgroups to maximise the probability of detection ($\pi_{k,t}$). Instead of an exhaustive search among all possible allocations of resources, we used a recursive algorithm. Assuming there are only two subgroups, i and j , the probability of detecting COVID-19 transmission can be expressed as:

$$\pi_{(k_i+k_j)*200,t} = 1 - \prod_t (1 - \varphi_{i,k_i*200,t})(1 - \varphi_{j,k_j*200,t}) \quad (\text{eq.5})$$

where the sum of k_i and k_j is $(n-1)$. Then, in the next step, $200n$ tests can be best allocated as:

$$\pi_{(k_i+k_j+1)*200,t} = \max \left(\frac{1 - \prod_t (1 - \varphi_{i,(k_i+1)*200,t})(1 - \varphi_{j,k_j*200,t})}{1 - \prod_t (1 - \varphi_{i,k_i*200,t})(1 - \varphi_{j,(k_j+1)*200,t})} \right) \quad (\text{eq.6})$$

where the sum of k_i and $k_j + 1$ and of $k_i + 1$ and k_j are both n . This recursive algorithm is applied to all nine surveillance subgroups to identify the optimal surveillance strategies, i.e., the allocation of COVID-19 tests that can achieve the highest $\pi_{k,t}$.

All analyses were done in R 4.0.0⁴¹. Code used is publicly available at <https://doi.org/10.5281/zenodo.4017354>⁴². An earlier version of this article can be found on medRxiv (<https://doi.org/10.1101/2020.06.27.20141440>).

Results

The subgroups-specific surveillance sensitivity

Surveillance sensitivity is the probability that on-going COVID-19 transmission (i.e., one or more cases) can be detected on a given day t . During an emerging yet undetected epidemic, the surveillance sensitivities of different subgroups are shown in Figure 2 for testing capacities between 0 and 100,000 tests/day. At the baseline scenario ($R_e = 2$), it takes 20 days for the

epidemic process to incur over 100 cases (17 and 25 days using unmitigated or 50% reduced R_e). At this point in the outbreak, while conducting 0.07 tests per thousand residents per day (t/k/day), the probability that a surveillance strategy exclusively targeting fever clinic patients and HCW can detect more than one COVID-19 case is 1.1% [UR: 0.6%, 1.3%] and 1.2% [UR: 1.0%, 2.2%], respectively. At the same daily testing level, the probability of detection is only 0.5% [UR: 0.3%, 0.6%] and 0.7% [UR: 0.4%, 0.9%], respectively, for respiratory departments patients and HCW. Among age-specific community groups, conducting surveillance among younger adults yields the highest surveillance sensitivity (0.4% [UR: 0.3%, 0.4%]).

Overall, without considering administrative constraints such as hospital service capacity, the surveillance sensitivities (i.e., the probability of capturing at least one infectious case) among HCW are slightly higher than those among patients. Within a hospital, fever clinics have the highest surveillance sensitivity, followed by respiratory departments, and then by other hospital departments. The most sensitive age-group for COVID-19 surveillance is younger adults. Surveillance sensitivities are comparable between younger adults in the community and respiratory patients in hospitals.

The surveillance sensitivity of patient-based surveillance strategies may experience within-year variability. We found that in northern hemisphere summer when other respiratory pathogens are less common in a city like Beijing, patient-based surveillance at respiratory departments become a more sensitive surveillance option; in winter, when other respiratory pathogens are common and the number of respiratory patients per day goes up, patient-based surveillance performs relatively worse than its annual average levels in terms of COVID-19 detection (*Extended data Section 3*)¹⁷.

Comparing fever clinics and respiratory departments

To further understand the potential benefits of fever clinics, we compared the probability of detecting at least one case of COVID-19 by day t using realistic administrative constraints (e.g., fever clinic service capacity) for Beijing, China (Figure 3). Using the parameters outlined in Table 1, we estimated that the maximum service capacity at fever clinic is 1,600 patients/day, respiratory departments 29,400 patients/day, and other hospital departments more than a quarter-million patients/day. If there is a capacity to conduct 1,600 tests/day (i.e., 0.07 t/k/day), the surveillance system was able to reach a 50% chance of detection among fever clinic patients 3 days earlier than among respiratory department patients. Using an unmitigated R_e shrunk the time gained to 2 days; a 50% reduced R_e of 1.4 expanded time gained to 4 days. To achieve an equivalent COVID-19 detection performance, patient-based surveillance in the respiratory department would need more than double the rate of testing (i.e. 3,600 tests/day, 0.17 t/k/day). When testing all patients arriving at respiratory departments (i.e., 29,400 tests per day, 1.35 t/k/day), we estimate a 12.3% [UR: 4.2%, 20.4%] and 25.2% [UR: 9.3%, 37.4%] chance to detect at least one COVID-19 case before there were a total of 50 and 100 cases in the simulated epidemic. While testing at maximum capacity in fever clinics

Figure 2. Surveillance sensitivity ($\phi_{t,k}$) is the probability of detecting at least one COVID-19 case on day t after the first infected case (i.e., seeding event) in a surveillance subgroup had a certain amount of daily testing been conducted. Vertical dashed lines represent thresholds of >10, >100, and >1000 cases in the population. Healthcare-related administrative constraints (e.g., number of HCWs available) are not yet incorporated into this output.

(i.e., 0.07 t/k/day), there is only a 1.6% [UR: 0.5%, 2.8%] and 3.0% [UR: 1.0%, 5.7%] chance of detecting at least one COVID-19 case before cumulative incidence reaches 50 and 100 cases.

Using the baseline scenario ($R_e = 2$), we found that while testing at maximum capacity at fever clinics (i.e., 0.07 t/k/day), the cumulative incidence has likely reached nearly 598 [95% eCI: 35, 2154] cases by the time first COVID-19 is detected (Figure 3). With the same amount of tests, the cumulative incidence has reached 1373 [95% eCI: 47, 5230] cases when the

first COVID-19 is detected at the respiratory department. Testing at maximum capacity at respiratory departments (i.e., 1.35 t/k/day) means by the time the first case is detected, the scope of the underlying outbreak is only 91 [95% eCI: 15, 273]. More information about these distributions is included in the Extended Data Section 4¹⁷.

Optimal strategies at different testing capacity

Figure 4 shows the highest probability of COVID-19 detection achievable at different daily testing capacities. These are also referred to as efficiency frontiers as no higher

Figure 3. Top: Probability of detection (π_t) at different daily testing capacities with healthcare infrastructure and operational constraints at fever clinics and respiratory departments by day t . Bottom: Empirical probability density functions of cumulative incidence by the time of first COVID-19 case detection among different surveillance subgroups and given different daily testing capacities. Labels show different daily rates (tests per thousand residents per day, $t/k/day$).

probability of COVID-19 detection can be achieved without improving the testing capacity. The probability of COVID-19 detection increases as cumulative incidence increases and as daily testing capacities increase. As expected, when cumulative incidence is already high, a small number of tests will already allow us to detect on-going transmission. When daily testing capacities increase, we observe a diminishing return on investment. The additional increase in the probability of detecting COVID-19 by every additional 200 tests conducted decreases as overall daily testing capacity increases. Distinct turning points on the efficiency frontiers indicate when the surveillance system switches from conducting more tests in a given subgroup to testing a new subgroup due to exhausting available individuals.

Figure 5 shows the specific composition of optimal surveillance strategies along the efficiency frontiers in Figure 4. The surveillance of COVID-19 with the purpose of early detection should prioritise testing among fever-clinic patients and HCWs. When more resources become available, respiratory department patients and HCWs should be included in the surveillance strategy. When more than 30,000 daily testing capacity is reached in a city with 24 million residents, testing among HCWs in other hospital departments and younger adults in the community should be included in the surveillance strategy. During conditions where cumulative incidences are extremely low (i.e., ≤ 100), including these two groups earlier on can improve the probability of detection (see also *Extended data Section 5*)¹⁷.

Figure 4. Efficiency frontiers show the optimal strategies at different levels of daily testing capacity and cumulative incidence. The optimal strategy is defined by the maximum probability of COVID-19 detections while considering all possible surveillance layers and subgroups at a given daily testing capacity. The transmission of COVID-19 is considered detected if one or more surveillance layers and subgroups detect at least one infectious case.

Figure 5. Allocation of resources (by proportion) to different surveillance subgroups along the efficiency frontiers.

The surveillance processes in this study currently assume randomness in healthcare-seeking decisions. In other words, clinically infectious COVID-19 individuals are equally likely to use different healthcare service options available to them. In reality, at the beginning of an outbreak, patients are likely going to use only a few fever clinics or respiratory departments out of all that are available due to spatial clustering. Consequently, HCWs across the whole city may not have an equal amount of increased exposure to potentially infectious COVID-19 patients. Using fever clinic HCWs as an example, we discovered that the optimal number of tests identified in this study should be allocated in a stratified manner (*Extended data Section 6*)¹⁷. For example, compared to randomly testing 30% of all fever clinic HCWs, testing a randomly 30% of HCWs in each fever clinic is slightly more efficient, especially when cumulative incidence is low.

Discussion

This study evaluated different allocations of resources for designing COVID-19 surveillance strategies in Beijing, China. We discovered surveillance sensitivity is highest at fever clinics, followed by respiratory departments, and then by community-based subgroups. Testing at maximum capacity among fever clinics patients (i.e., 1,600 tests/day, 0.07 t/k/day) allows us 50% probability to detect on-going transmission by day 29 after the first infection given R_t of 2 (day 25 when R_t of 2.7, day 35 when R_t of 1.4). To achieve similar levels of efficiency, a surveillance system based in the respiratory department would need more than twice the daily testing capacity. Testing at maximum capacity in respiratory patients (29,400 tests/day, 1.35 t/k/day) allows us a 50% probability to detect on-going transmission a week earlier. Surveillance sensitivity is slightly higher among HCWs compared to patients in hospitals given a within-year average condition. However, when other respiratory pathogens are less common, surveillance among fever clinic and respiratory department patients become significantly more sensitive.

The surveillance system in this study is particularly relevant to locations where epidemic “suppression” strategies (e.g., school and workplace closures combined with testing and contact tracing) have been successful in reducing COVID-19 incidence to a very low level, such as China, South Korea, and New Zealand³. These countries may experience extended periods without any new COVID-19 cases detected. However, epidemic risks will persist due to the non-trivial proportion of subclinical cases⁶, importation from other locations⁸, and the potentially short-lived immunity following infection⁴³. Sporadic infection chains have already been observed in countries that previously reported no new cases for a while, such as China and South Korea, both of whom have relied on intensive testing policies to guide their follow-up interventions and to prevent large outbreaks. As more countries head into the post epidemic peak phases, surveillance and early detection will continue to play a central role in COVID-19 response. The population age distribution, contact patterns, and healthcare system administrative and service capacities from Beijing were used to parameterise the model in this study. The framework is easily transferable to

studying other health systems. A wide range of testing capacities is examined, allowing national or subnational public health entities at different resource levels to benefit from the concepts derived here.

The concepts of fever clinics and respiratory departments should be interpreted broadly as triaging systems, each with a different baseline population defined by different sets of symptoms of various degree of syndromic specificity, leading to different surveillance sensitivity to detect COVID-19. In other words, the more specific symptoms are related to COVID-19, the higher the surveillance sensitivity achievable. An internal medicine department, for example, has lower surveillance sensitivity compared to the respiratory department but is more sensitive than an oncology department. We quantified the benefits of setting up a triage system such as fever clinics. The current criteria for a patient to be admitted into fever clinics follow the World Health Organisation’s definition of influenza-like illness (defined as fever $\geq 38^\circ\text{C}$ and cough or sore throat)⁴⁴. In response to the ongoing outbreak started from Beijing’s Xinfadi Market, some hospitals have revised the body temperature threshold down to 37.3°C ⁴⁵.

We are aware of additional triaging criteria based on the assessment of dyspnea, hypoxia, and chest x-ray interpretation¹². These criteria may further decrease the background populations for fever clinics and respiratory departments, increasing surveillance sensitivity and thus reducing the number of tests needed. In Mao *et al.*⁴⁶, based on only expert assessment and (when needed) chest x-ray, fever clinics in Shanghai were able to triage non-COVID-19 cases with 100% accuracy. This level of triaging accuracy, however, is not always possible. A COVID-19 transmission cluster in Harbin, China, included a patient who was triaged to be non-COVID-19, admitted for cerebral stroke, and thus not isolated. This patient, directly and indirectly, infected 35 persons including three HCWs while hospitalised⁴⁷.

Another potential mechanism that can be used to reduce the number of tests needed is the pooling of samples. Instead of testing the sample of each person individually, this method combines swab specimens from many and tests them collectively. When positive pools of specimens are identified, additional individual-based tests will be carried out only within these pools. This method has been used for influenza surveillance and has been used for a one-time community-based COVID-19 screening in Wuhan^{48,49}. While the pooling methods may not meet diagnostic needs in a clinical setting (e.g., timeliness), community-based surveillance could potentially rely on this approach to increase coverage. However, specific laboratory standards may need further evidence support.

Routine testing in the community (other hospital departments or age-specific community groups) is less likely to yield a high probability of detecting infections but can be added if early detection is prioritised, in which case we find that the highest probability for detection is among younger adults. Although many studies have found older adults to be the most susceptible

age group with the highest clinical fraction who therefore are most likely to seek healthcare, surveillance of younger adults has higher sensitivity, possibly for two main reasons: (1) at the initial phase of an outbreak, younger adults may be more likely to be infected due to higher numbers of daily contacts¹⁶; (2) a larger proportion of COVID-19 infections among younger adults may never progress clinically and thus may go undetected with symptom-based surveillance in the healthcare systems; infections among older adults, on the other hand, can already be detected via surveillance in healthcare settings and thus do not need further community testing^{1,6,50}.

This study only considers virological tests based on PCR to detect COVID-19 infections and did not consider serological tests for several reasons. Firstly, the window of possible viral RNA detection occurs earlier than seroconversion for COVID-19^{51,52}. The rate of seroconversion among subclinical cases is largely unknown. Serological tests thus are suboptimal given the objective of early outbreak detection. Secondly, it remains unclear if current serological tests can differentiate between current and previous infections. And last but not the least, follow-up interventions to interrupt onward transmission, such as contact tracing and quarantine, given serological test results, would be challenging. The window of potential infectiousness may be uncertain and long-passed, making it difficult for infected individuals to recall their close contacts.

This modelling study has limitations. Firstly, an important assumption in this study is that clinically infectious COVID-19 patients would seek medical care at the same rate as patients with other respiratory pathogens. For example, if 10% of patients infected with other respiratory pathogens seek care, then 10% of COVID-19 patients will seek care. However, this assumption may not be valid. Clinically, COVID-19 patients may be more likely to seek care due to pandemic awareness. They may also be less likely to seek care due to uncertainty around associated healthcare costs or the risk perception surrounding healthcare settings. Public messaging that motivates people to use healthcare may increase the sensitivity of hospital-based COVID-19 surveillance at fever clinics and respiratory departments.

Secondly, it is also important to note that there is still much unknown about SARS-CoV-2, a novel pathogen. The results of this paper, thus, is built on our best knowledge, which may be challenged in the future. The underlying epidemic processes in this study assumes the population to be largely susceptible at the beginning with a reproduction number of 2. This assumption is justifiable based on low seropositivity in the general population and among HCWs^{21,22,53}. However, a smaller reproduction number may be required if seroprevalence is high⁵⁴. In that case, epidemic processes will be slower compared to shown here, increasing the time gained to respond via public health surveillance. However, the order of prioritisation among surveillance layers and subgroups as well as the distribution of resources will not change unless large differentials in terms of seropositivity are observed by age or occupation groups.

Thirdly, as population-level prevalence decreases, the positive predictive value of any individual test will necessarily be lowered. Despite the high diagnostic specificity of PCR, there may be a small amount of false-positive tests. For example, in an environment completely free of SARS-CoV-2, conducting 30,000 tests/day may still lead to three false-positive test results if the diagnostic specificity is 99.99%. Hence, as testing capacity increases, almost but not quite a perfect testing specificity may lead to false alarms. This will need to be accounted for when deciding how to act upon identified COVID-19 cases. In practice, imperfect diagnostic specificity (resulting from factors such as laboratory contamination), could be compensated for by re-testing of the patients or samples. This, however, was not explicitly accounted for in our model although we do not expect the number of tests required for re-testing would be high at the beginning of outbreaks.

Highly sensitive COVID-19 surveillance contributes to timely outbreak detection, thereby enabling and guiding a swift and targeted response associated with a high probability of containment. In this study, we assessed the surveillance sensitivity in different surveillance layers and subgroups. While designing a COVID-19 surveillance system, prioritisation of fever clinics over respiratory departments and of patients over HCWs tend to optimise for higher COVID-19 detection probability given limited testing capacity. Community-based testing that targets non-respiratory patients and HCWs or age-specific community groups can capture subclinical infections but may only be considered when more testing capacity becomes available. Future research may further assess the value of information on COVID-19 surveillance systems by estimating the on-ward transmission prevented.

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Extended data

Figshare: [Supplemental Material] "Designing a Multi-layered Surveillance Approach to Detecting SARS-CoV-2: A Modelling Study. <https://doi.org/10.6084/m9.figshare.12925004.v1>

This project contains Sections 1–6 of the extended data.

This project is available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

The model used in this article is available at: https://github.com/yangclaraliu/covid_surveillance_strategy.

Archived model at time of publication: <https://doi.org/10.5281/zenodo.40173542>.

License: [Creative Commons Zero v1.0 Universal](#).

Author information

Wenfeng Gong and Samuel Clifford are joint-second authors; Stefan Flasche and Petra Klepac are joint-senior authors.

Acknowledgements

CMMID-COVID Working Group Members (order determined at random):

Megan Auzenberg and Kathleen O'Reilly are funded by the Bill and Melinda Gates Foundation (OPP1191821). Matthew Quaife is funded by the European Research Council Starting Grant (#757699) and the Bill and Melinda Gates Foundation (INV-001754); Rosalind M Eggo is funded by Health Data Research UK (MR/S003975/1) and the Medical Research Council (MC_PC 19065); Hamish P Gibbs is funded by the Department of Health and Social Care (UK, ITCRZ 03010); Alicia Rosello is funded by the National Institute of Health Research (UK, PR-OD-1017-20002); Oliver Brady is funded by the Wellcome Trust (206471/Z/17/Z); Eleanor M Rees is funded by the Medical Research Council's (UK) London Intercollegiate Doctoral Training Program Studentship (MR/N013638/1); Kevin van Zandvoort is funded by the UK Government Department for International Development and Wellcome Trust Epidemic Preparedness Coronavirus Research Programme (221303/Z/20/Z); Jon C Emery is funded by the European Research Council Starting Grant (#757699); Nicholas G. Davies is funded by the National Institute of Health Research (UK) Health Protection Unit for Immunisation (NIHR200929); Georgia R Gore-Langton is funded by the Medical Research Council's (UK) London Intercollegiate Doctoral Training Program Studentship (MR/N013638/1); David Simons is funded by the Biotechnology and Biological Sciences Research Council London Interdisciplinary Doctoral Program Studentship (BB/M009513/1); Amy Gimma is funded by the Global Challenges Research Fund (ES/P010873/1); Akira Endo is funded by the Nakajima Foundation and the Alan Turing Institute; Sam Abbott is funded by the Wellcome Trust (210758/Z/18/Z); Quentin J Leclerc is funded by the Medical Research Council's

(UK) London Intercollegiate Doctoral Training Program Studentship (MR/N013638/1); Timothy W Russell is funded by the Wellcome Trust (206250/Z/17/Z); Emily S Nightingale is funded by the Bill and Melinda Gates Foundation (OPP1183986); Simon R Procter is funded by the Bill and Melinda Gates Foundation (OPP1180644); Kiesha Prem is funded by the Bill and Melinda Gates Foundation (INV-003174) and the European Commission (101003688), Gwenan M Knight is funded by the Medical Research Council (UK, MR/P014658/1); Charlie Diamond is funded by the National Institute of Health Research (16/137/109), Joel Hellewell is funded by the Wellcome Trust (210758/Z/18/Z); Christopher I Jarvis, the Global Challenges Research Fund (ES/P010873/1); Carl A B Pearson is funded by the Bill and Melinda Gates Foundation (OPP1184344) and the UK Government Department for International Development and Wellcome Trust Epidemic Preparedness Coronavirus Research Programme (221303/Z/20/Z); Billy J Quilty is funded by the National Institute of Health Research (UK, 16/137/109 & 16/136/46); W John Edmunds is funded by the European Commission (101003688); Rein M G J Houben is funded by the European Research Council Starting Grant (#757699); Sophie R Meakin is funded by the Wellcome Trust (210758/Z/18/Z); Rachel Lowe is funded by the Royal Society Dorothy Hodgkin Fellowship; Fiona Yueqian Sun is funded by the National Institute of Health Research (UK, 16/137/109); Graham Medley is funded by the Bill and Melinda Gates Foundation (OPP1184344); Thibaut Jombart is funded by the Research Council UK/ Economics and Social Research Council (ES/P010873/1), the UK Public Health Rapid Support Team, and the National Institute of Health Research (UK) Health Protection Research Unit in Modelling Methodology; James D Munday is funded by the Wellcome Trust (210758/Z/18/Z); Adam J Kucharski is funded by the Wellcome Trust (206250/Z/17/Z); C Julian Villabona-Arenas and Katherine E. Atkins are funded by the European Research Council Starting Grant (#757688); Nikos I Bosse and Sebastian Funk are funded by the Wellcome Trust (210758/Z/18/Z).

References

- Li Q, Guan X, Wu P, *et al.*: **Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.** *N Engl J Med.* 2020; **382**(13): 1199–1207.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- World Health Organisation: **Director-General's opening remarks at the media briefing on COVID-19-11 March 2020.** 2020.
[Reference Source](#)
- World Health Organisation: **COVID-19 situation reports.** 2020; published online June.
[Reference Source](#)
- Kucharski AJ, Russell TW, Diamond C, *et al.*: **Early dynamics of transmission and control of COVID-19: a mathematical modelling study.** *Lancet Infect Dis.* 2020; **20**(5): 553–558.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Riou J, Althaus CL: **Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020.** *Euro Surveill.* 2020; **25**(4): 2000058.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Davies NG, Klepac P, Liu Y, *et al.*: **Age-dependent effects in the transmission and control of COVID-19 epidemics.** *Nat Med.* 2020; **26**(8): 1205–1211.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rothan HA, Byrareddy SN: **The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.** *J Autoimmun.* 2020; **109**: 102433.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Russell TW, Wu J, Clifford S, *et al.*: **The effect of international travel restrictions on internal spread of COVID-19.** *medRxiv.* 2020; 2020.07.12.20152298.
[Publisher Full Text](#)
- Ferguson N, Laydon D, Nedjati Gilani G, *et al.*: **Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand.** Imperial College London, 2020.
[Publisher Full Text](#)

10. Shi G: **Five confirmed patients live in the same residential complex.** 2020. [Reference Source](#)
11. World Health Organization: **Surveillance strategies for COVID-19 Human Infection - Interim Guidance.** World Health Organization, 2020. [Reference Source](#)
12. Zhang J, Zhou L, Yang Y, *et al.*: **Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics.** *Lancet Respir Med.* 2020; 8(3): e11–e12. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Klepac P, Caswell H: **The stage-structured epidemic: linking disease and demography with a multi-state matrix approach model.** *Theor Ecol.* 2011; 4: 301–319. [Publisher Full Text](#)
14. Keeling MJ, Tildesley MJ, Atkins BD, *et al.*: **The impact of school reopening on the spread of COVID-19 in England.** *Infectious Diseases (except HIV/AIDS).* 2020. [Reference Source](#)
15. Davies NG, Kucharski AJ, Eggo RM, *et al.*: **Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study.** *Lancet Public Health.* 2020; 5(7): e375–e385. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Prem K, Cook AR, Jit M: **Projecting social contact matrices in 152 countries using contact surveys and demographic data.** *PLoS Comput Biol.* 2017; 13(9): e1005697. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Liu Y, Gong W, Clifford S, *et al.*: **[Supplemental Material] “Designing a Multi-layered Surveillance Approach to Detecting SARS-CoV-2: A Modelling Study.** 2020. [Publisher Full Text](#)
18. Chau NVV, Lam VT, Dung NT, *et al.*: **The natural history and transmission potential of asymptomatic SARS-CoV-2 infection.** Oxford Academic, 2020. [Reference Source](#)
19. Grassly N, Pons Salort M, Parker E, *et al.*: **Report 16: Role of testing in COVID-19 control.** Imperial College London, 2020. [Publisher Full Text](#)
20. Seow J, Graham C, Merrick B, *et al.*: **Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection.** *medRxiv.* 2020; 2020.07.09.20148429. [Publisher Full Text](#)
21. Xu X, Sun J, Nie S, *et al.*: **Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China.** *Nat Med.* 2020; 26(8): 1193–1195. [PubMed Abstract](#) | [Publisher Full Text](#)
22. Stringhini S, Wisniak A, Piumatti G, *et al.*: **Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.** *Lancet.* 2020; 396(10247): 313–319. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Backer JA, Klinkenberg D, Wallinga J: **Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020.** *Euro Surveill.* 2020; 25(5): 2000062. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Liu Y, Group C for MM of ID nCoV W Funk S, *et al.*: **The contribution of pre-symptomatic infection to the transmission dynamics of COVID-2019.** *Wellcome Open Res.* 2020; 5: 58. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. He X, Lau EH, Wu P, *et al.*: **Temporal dynamics in viral shedding and transmissibility of COVID-19.** *Infectious Diseases (except HIV/AIDS).* 2020. [Publisher Full Text](#)
26. National Bureau of Statistics of China: **Annual Data.** 2020.
27. China National Influenza Center: **China Influenza Weekly Report.** 2020. [Reference Source](#)
28. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators: **Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.** *Lancet.* 2018; 392(10159): 1789–1858. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Wan T: **Beijing can now test more than 90,000 people in a day - everyone who needs a test should be able to get one.** 2020. [Reference Source](#)
30. Gong X: **Fever clinic in Beijing had more than 20000 cases in one week, identifying 145 suspected cases.** 2020.
31. Zhang W, Zhen G, Shi J, *et al.*: **The effect of air pollution on outpatient visits for respiratory diseases in Shunyi district Beijing.** *Chinese Journal of Health Statistics.* 2017. [Reference Source](#)
32. China National Health Commission: **China Health Statistics Yearbook.** 2017. [Reference Source](#)
33. Zhao D; Beijing Health Bureau Fever Clinic Project Team: **[Evaluation on the Functions and Cost of ‘Fever Clinics’ During the Period of Severe Acute Respiratory Syndrome Epidemics in Beijing].** *Zhonghua Liu Xing Bing Xue Za Zhi.* 2003; 24(11): 999–1004. [PubMed Abstract](#)
34. Georgia Department of Public Health: **COVID-19 Testing/Direct Patient Lines.** 2020. [Reference Source](#)
35. Jia X: **Beijing: the following four groups of people should be tested even without.** *Xinhua Net.* 2020; published online May. [Reference Source](#)
36. Jiang L, Ng IHL, Hou Y, *et al.*: **Infectious disease transmission: survey of contacts between hospital-based healthcare workers and working adults from the general population.** *J Hosp Infect.* 2018; 98(4): 404–411. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Chen J: **Hubei can now test 89,000 people in a day.** 2020.
38. Department of Health and Social Care: **UK reaches 200,000 coronavirus testing capacity target a day early.** GOV.UK, 2020. [Reference Source](#)
39. Devlin H: **Is 100,000 tests a day an effective strategy against coronavirus?** *The Guardian.* 2020. [Reference Source](#)
40. National Bureau of Statistics of China: **China Statistical Yearbook (2018).** 2018. (accessed April 30, 2020).
41. R Core Team: **R: A language and environment for statistical computing.** Vienna, Austria: R Foundation for Statistical Computing, 2020. [Reference Source](#)
42. Liu Y, Gong W, Clifford S, *et al.*: **yangclaraliu/covid_surveillance_strategy: WOR Submission.** Zenodo, 2020. <http://www.doi.org/10.5281/zenodo.4017354>
43. Galanti M, Shaman J: **Direct observation of repeated infections with endemic coronaviruses.** 2020. [Publisher Full Text](#)
44. Feng L, Feng S, Chen T, *et al.*: **Burden of influenza-associated outpatient influenza-like illness consultations in China, 2006–2015: A population-based study.** *Influenza Other Respir Viruses.* 2020; 14(2): 162–172. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Beijing Yo'an Hospital: **With an on-going outbreak, Beijing Yo'an Hospital will try its best to service all patients.** 2020. [Reference Source](#)
46. Mao B, Liu Y, Chai YH, *et al.*: **Assessing risk factors for SARS-CoV-2 infection in patients presenting with symptoms in Shanghai, China: a multicentre, observational cohort study.** *Lancet Digit Health.* 2020; 2(6): e323–e330. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Liu X: **How did one patient spread to 35 in a hospital? Investigation of a nosocomial transmission chain.** *Xinhua Net.* 2020; published online April. [Reference Source](#)
48. Van TT, Miller J, Warshauer DM, *et al.*: **Pooling Nasopharyngeal/Throat Swab Specimens To Increase Testing Capacity for Influenza Viruses by PCR.** *J Clin Microbiol.* 2012; 50(3): 891–896. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Liao Y, Xue S: **Jiang'an district of Wuhan has pooled samples for PCR testing.** 2020. [Reference Source](#)
50. Zhang J, Litvinova M, Wang W, *et al.*: **Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study.** *Lancet Infect Dis.* 2020; 20(7): 793–802. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Wölfel R, Corman VM, Guggemos W, *et al.*: **Virological assessment of hospitalized patients with COVID-2019.** *Nature.* 2020; 581(7809): 465–469. [PubMed Abstract](#) | [Publisher Full Text](#)
52. Long QX, Liu BZ, Deng HJ, *et al.*: **Antibody responses to SARS-CoV-2 in patients with COVID-19.** *Nat Med.* 2020; 26(6): 845–848. [PubMed Abstract](#) | [Publisher Full Text](#)
53. Steensels D, Oris E, Coninx L, *et al.*: **Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium.** *JAMA.* 2020; 324(2): 195–197. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Wu LP, Wang NC, Chang YH, *et al.*: **Duration of antibody responses after severe acute respiratory syndrome.** *Emerg Infect Dis.* 2007; 13(10): 1562–1564. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status: ? ?

Version 1

Reviewer Report 10 November 2020

<https://doi.org/10.21956/wellcomeopenres.17858.r40827>

© 2020 Wang W. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Weibing Wang

School of Public Health, Fudan University, Shanghai, China

Based on a currently more recognized COVID-19 model framework, the study considered the part of recovered population with PCR-positive who are actually no longer infectious by further subdividing the recovered population compartment. This brings the extended SEIR model framework closer to reality.

This study considered the actual situation of different detection scenarios (e.g., fever clinic, respiratory department, etc.), and evaluated how to allocate different medical resources. For example, in the early stage of epidemic, patients in fever clinic should be given priority to be tested. This also provides scientific advice to the actual detection departments, which can more quickly predict the number of people who have been infected when the first infected person is detected, thus giving early warning to relevant departments for further prevention and control work.

There are some issues need to answer or consider:

1. The author used an effective reproduction number (R_e) of 2 that reflects a 25% reduction from 2.7 as a result of public health measures, which need to give more evidence. As a number of publications has shown the effective implementation of NPIs can reduce the R_e below 1.
2. Regarding the assumption 2 – ‘those with a subclinical COVID-19 infection who are seeking care for non-respiratory causes may be detected in other hospital departments’, there is no guarantee that a patient with subclinical COVID-19 will take the PCR test in other departments.
3. Regarding the assumption 3 – ‘those with a COVID-19 infection who do not actively seek care may be detected in the community whether they exhibit symptoms or not’, which is true only when the outbreak has led to community transmission.
4. Your model indicated that the testing at such a high level (e.g. 63,000 samples in a single

day) may not be sustainable. However, the measurement of Qingdao and Yunnan have approved the testing capacity may not be a problem in cities in the country like China and other countries with abundant resources.

5. The large-scale use of pooling testing will compromise the sensitivity and specificity of COVID-19 testing, which has been included in the guideline in China, and you may need to consider it in your modeling.
6. I did not see how the close contacts would be tested and detected because of exposure, which was however very important for the measurements for control of epidemics.
7. The author should pay more attention to the details of the article. Errors like these may cause confusion in the reader's understanding, for example, the formula in line 7 on page 2 of the attachment seems to be ambiguous which should be clinical infectious compartments.
8. A few of newly published papers may need to be included in the references.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: epidemiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 09 November 2020

<https://doi.org/10.21956/wellcomeopenres.17858.r41178>

© 2020 Pei S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sen Pei

Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA

In this study, authors used a dynamic SEIR-type model to investigate different surveillance strategies among healthcare workers, hospital patients and general community to detect a new COVID-19 outbreak in population. Using extensive model simulations, authors evaluated the surveillance sensitivity in different settings with various testing capacities, and proposed a multi-layer surveillance approach that optimally allocates testing resources. Results from this modeling work have direct implications in COVID control and can inform allocation of testing to achieve rapid detection of the onset of a new outbreak. The study is in general technically sound, and the results are clearly communicated. Here I have a few questions and suggestions that I hope authors find useful.

1. The study employed a deterministic compartmental model and assumed the new outbreak is initiated by a single exposed person. As the initial transmission dynamics is highly stochastic, it is more appropriate to use a stochastic version of the model. This model stochasticity could also potentially affect the surveillance sensitivity and uncertainty in the results, for instance, Figure 3.
2. Figure 2 is hard to read using the current color map. A contour map would be better.
3. In Table 1, does the PCR diagnostic sensitivity depend on the sampling time relative to infection time?
4. It would be good to explain the meaning of crosses in Table 2.
5. In the model, HCWs are assumed to face a higher infection risk than patients due to prolonged exposures. However, there are reports showing that the use of PPE actually could reduce the infection risk compared with general population. A discussion on this factor would be helpful.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Infectious disease modeling, epidemiology, statistical inference

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.